Saturday, October 31, 2026

Burry Shorts $1B in AI as Berkshire Hoards $397B Cash — Global Markets Watch

Michael Burry's Scion Asset Management has opened a roughly $1 billion short position against AI stocks, comparing the sector to the 2008 housing bubble. Simultaneously, Warren Buffett's Berkshire Hathaway has accumulated a record $397 billion in cash — a defensive posture that has historically preceded broad market dislocations. Together, the two signals are drawing attention from investors across Asia, Europe, and the Americas.

LM Salvado
LM Salvado

May 24, 2026

Burry Shorts $1B in AI as Berkshire Hoards $397B Cash — Global Markets Watch
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

Michael Burry has placed a roughly $1 billion bet against AI stocks, publicly calling the sector a 2008-style bubble.1 At the same time, Berkshire Hathaway's cash reserves have hit a record billions — the largest defensive position Warren Buffett has ever held.

Three bearish signals have converged simultaneously: Burry's short position, his published Substack commentary, and Berkshire's record cash pile.1 That kind of alignment among contrarian investors is historically rare and has drawn scrutiny from portfolio managers from London to Tokyo.

Burry's 2008 housing short preceded the sector's collapse by roughly 12 months.1 He is now applying that same framework to AI — a sector that absorbed hundreds of billions in global investment between 2023 and 2025, with valuations increasingly detached from near-term revenue across US, European, and Asian markets alike.

Berkshire's cash accumulation adds a systemic dimension. Buffett's record cash positions have historically foreshadowed wide market dislocations, not just sector corrections.1 If that pattern holds, exposure extends beyond AI stocks to global equity markets broadly.

The timing is sensitive for AI capital markets worldwide. Venture investment in AI infrastructure, model development, and enterprise software surged through 2024 and 2025 — not only in Silicon Valley, but in London, Paris, Singapore, Seoul, and Riyadh. Valuation compression in US public markets typically flows into late-stage private valuations within one to two quarters, tightening funding globally.

The 3-to-6-month correction window implied by this signal cluster coincides with a critical period for AI companies eyeing public listings or secondary rounds across major exchanges.1 Sustained weakness in AI stock prices would reduce appetite for those deals and compress exit multiples for investors on every continent.

Burry and Buffett rarely move in the same direction. When they do, history suggests the combined signal carries weight — even if the precise timing of any correction remains uncertain.

In this story · Knowledge Files

About this analysis

This is a Via News analysis. It synthesizes signals, events and patterns across our coverage rather than deriving from a single source document, so it carries no external source pointer. Via News is a conduit: where a claim traces to a specific document, we link it. How we source

LM Salvado
LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com